,

The PROCEED trial KCSG BR11-01 phase III multicenter randomized open-label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

,

Selection of systemic treatment after CNS metastasis

,

Update in Brain metastasis

,

HER2 negative breast cancer

,

Does participation in clinical trials influence on survival in patients with metastatic breast cancer?